comprehensive -WSS

comprehensive

author：explore 2025-08-26 10:52:58 - browse：86

The Amgen booth at ESMO in Madrid. Andrew Joseph/STAT

MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.

The data, reported here Friday at the annual meeting of European Society for Medical Oncology, come from a Phase 2 trial of the drug, called tarlatamab. But they drew greater interest because Amgen has described the study as “potentially registrational,” and the trial results were also published Friday in the New England Journal of Medicine.

“It’s a single arm study, but the results are amazing,” said Silke Gillessen, the scientific chair of ESMO 2023 and an oncologist at the Oncology Institute of Southern Switzerland, noting that advances in small cell lung cancer have been slow to come.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Teach medical students about patients with intellectual disabilities

focus

WSS

Teach medical students about patients with intellectual disabilities

Why the quest to eradicate polio has stumbled

Assistant physicians can help address the primary care shortage

Pharma patents targeted by Biden in move to slash drug prices

Radiology is caught between AI's potential and concern for patients

Pharma patents targeted by Biden in move to slash drug prices

knowledge

comprehensive

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Patients' immediate access to test results puts radiologists in a bind

Cancer drug shortages should be causing more outrage

Akili changes sales model for its ADHD video game treatment

Apple is now the first public company to be valued at $3 trillion

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Cancer drug shortages should be causing more outrage

PBMs drew scrutiny in House hearing — and so did pharma

Alkermes shareholders re

Leukemia patients are helped by Syndax's new type of therapy

hotspot

Why sickle cell disease is getting the first CRISPR treatment

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

House panel takes first step toward fixing drug shortages

Radiology is caught between AI's potential and concern for patients

'A game

Why the quest to eradicate polio has stumbled

focus

focus

explore

leisure time